Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study

 

• Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM)
  
• Greater than 90% mean serum TTR reductions after a single dose of NTLA-2001 were sustained at both doses tested, with follow-up now reaching four to six months
• NTLA-2001 was generally well-tolerated
  

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today presented additional interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis in collaboration with Regeneron Pharmaceuticals. Results were presented in a Late-Breaking Science oral presentation at the American Heart Association (AHA) Scientific Sessions 2022, held November 5 – 7 in Chicago, Illinois.

https://www.marketscreener.com/quote/stock/INTELLIA-THERAPEUTICS-IN-27506682/news/Intellia-Presents-Updated-Interim-Data-from-the-Cardiomyopathy-Arm-of-Ongoing-Phase-1-Study-of-NTLA-42221996/